| answer text |
<p>NHS England has advised that cancer drugs that are assessed by the National Institute
for Health and Care Excellence (NICE) as having both key clinical uncertainties and
plausible cost effectiveness can enter the Cancer Drugs Fund (CDF) for evaluation
with a view to future NICE re-appraisal once there is sufficient data from continuing
clinical trials and/or data collection in the CDF.</p><p> </p><p>The duration in the
CDF for a cancer drug is determined on an individual basis by the time required for
such data development/collection to take place. This will depend on the disease concerned,
the data that needs to be examined, the clinical trials that may be already running,
and considerations of cancer treatment pathways in England. The time that a drug stays
in the CDF is therefore individually assessed and agreed with NHS England, NICE and
the company concerned.</p>
|
 |
